RESUMEN
The American Society for Colposcopy and Cervical Pathology (ASCCP) Colposcopy Standards recommendations address the role of colposcopy and directed biopsy for cervical cancer prevention in the United States (US). The recommendations were developed by an expert working group appointed by ASCCP's Board of Directors. An extensive literature review was conducted and supplemented by a systematic review and meta-analysis of unpublished data. In addition, a survey of practicing colposcopists was conducted to assess current colposcopy practice in the US. Recommendations were approved by the working group members, and the final revisions were made based on comments received from the public. The recommendations cover terminology, risk-based colposcopy, colposcopy procedures, and colposcopy adjuncts. The ASCCP Colposcopy Standards recommendations are an important step toward raising the standard of colposcopy services delivered to women in the US. Because cervical cancer screening programs are currently undergoing important changes that may affect colposcopy performance, updates to some of the current recommendations may be necessary in the future.
Asunto(s)
Colposcopía/métodos , Colposcopía/normas , Detección Precoz del Cáncer/métodos , Detección Precoz del Cáncer/normas , Neoplasias del Cuello Uterino/prevención & control , Femenino , Humanos , Estados UnidosRESUMEN
Women who have abnormal Papanicolaou test results may undergo colposcopy to determine the biopsy site for histologic evaluation. Traditional grading systems do not accurately assess lesion severity because colposcopic impression alone is unreliable for diagnosis. The likelihood of finding cervical intraepithelial neoplasia grade 2 or higher increases when two or more cervical biopsies are performed. Excisional and ablative methods have similar treatment outcomes for the eradication of cervical intraepithelial neoplasia. However, diagnostic excisional methods, including loop electrosurgical excision procedure and cold knife conization, are associated with an increased risk of adverse obstetric outcomes, such as preterm labor and low birth weight. Methods of endometrial assessment have a high sensitivity for detecting endometrial carcinoma and benign causes of uterine bleeding without unnecessary procedures. Endometrial biopsy can reliably detect carcinoma involving a large portion of the endometrium, but is suboptimal for diagnosing focal lesions. A 3- to 4-mm cutoff for endometrial thickness on transvaginal ultrasonography yields the highest sensitivity to exclude endometrial carcinoma in postmenopausal women. Saline infusion sonohysteroscopy can differentiate globally thickened endometrium amenable to endometrial biopsy from focal abnormalities best assessed by hysteroscopy. Hysteroscopy with directed biopsy is the most sensitive and specific method of diagnosing endometrial carcinoma, other than hysterectomy.
Asunto(s)
Cuello del Útero/patología , Colposcopía , Neoplasias Endometriales/patología , Endometrio/patología , Displasia del Cuello del Útero/patología , Displasia del Cuello del Útero/cirugía , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/cirugía , Biopsia , Legrado , Neoplasias Endometriales/diagnóstico por imagen , Femenino , Humanos , Histeroscopía , Terapia por Láser , UltrasonografíaRESUMEN
INTRODUCTION: Proposed changes to family medicine maternity care training requirements, including a 2-tiered basic and advanced curriculum, have raised questions about their perceived feasibility and impact. The goal of this study was to elicit family medicine obstetrics faculty plans to adopt changes in their maternity care training of family physicians. METHODS: We surveyed obstetrics curriculum directors at 423 family medicine residency programs, eliciting their plans to accommodate proposed maternity care training requirements. RESULTS: Two hundred nine programs participated (49.4% response rate). Of the curriculum adoption plans reported by directors, 41.7% anticipated using both curriculum models, 19.6% anticipated using the advanced model, 3.9% anticipated using the basic model, and 23.5% had no changes planned for their obstetrics curricula. CONCLUSIONS: Most programs plan structured changes, but a significant minority of programs plan no change to their curriculum based on proposed maternity care requirements.
Asunto(s)
Curriculum/normas , Medicina Familiar y Comunitaria/educación , Internado y Residencia/normas , Modelos Educacionales , Obstetricia/educación , Acreditación , Encuestas de Atención de la Salud , Internado y Residencia/métodos , Estados UnidosRESUMEN
New data have emerged since publication of the American Society for Colposcopy and Cervical Pathology's 2001 consensus guidelines for management of abnormal cervical cytology and histology. The 2006 guidelines include recommendations for special populations (i.e., adolescents and pregnant women). Human papillomavirus testing is now included for management of atypical glandular cytology, for follow-up after treatment for cervical intraepithelial neoplasia, and in combination with cytologic screening in women 30 years and older. The preferred management of atypical squamous cells of undetermined significance in adult women is reflex human papillomavirus DNA testing. Colposcopy is recommended for adult women with low-grade squamous intraepithelial lesion, atypical glandular cells, high-grade intraepithelial neoplasia, and atypical squamous cells-cannot exclude high-grade intraepithelial neoplasia. Cervical intraepithelial neoplasia, grade 1 can be managed conservatively in adult women, but treatment for cervical intraepithelial neoplasia, grades 2 and 3 is recommended. Immediate treatment is an option for adult women but not for adolescents with high-grade squamous intraepithelial lesion. Conservative management of adolescents with any cytologic or histologic diagnosis except specified cervical intraepithelial neoplasia, grade 3 and adenocarcinoma in situ is recommended. Colposcopy is preferred for pregnant women with low-grade squamous intraepithelial lesion and high-grade squamous intraepithelial lesion, but evaluation of the former may be deferred until no earlier than six weeks postpartum. Treatment during pregnancy is unacceptable unless invasive carcinoma is identified.
Asunto(s)
Cuello del Útero/patología , Lesiones Precancerosas/diagnóstico , Displasia del Cuello del Útero/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Frotis Vaginal , Adolescente , Adulto , Alphapapillomavirus/genética , Cuello del Útero/virología , Colposcopía , ADN Viral/análisis , Femenino , Humanos , Infecciones por Papillomavirus/diagnóstico , Lesiones Precancerosas/virología , Neoplasias del Cuello Uterino/virología , Frotis Vaginal/normas , Frotis Vaginal/estadística & datos numéricos , Adulto Joven , Displasia del Cuello del Útero/virologíaRESUMEN
Menorrhagia is defined as excessive uterine bleeding occurring at regular intervals or prolonged uterine bleeding lasting more than seven days. The classic definition of menorrhagia (i.e., greater than 80 mL of blood loss per cycle) is rarely used clinically. Women describe the loss or reduction of daily activities as more important than the actual volume of bleeding. Routine testing of all women with menorrhagia for inherited coagulation disorders is unnecessary. Saline infusion sonohysteroscopy detects intracavitary abnormalities such as endometrial polyps or uterine leiomyoma and is less expensive and invasive than hysteroscopy. Endometrial biopsy is effective for diagnosing precancerous lesions and adenocarcinoma but not for intracavitary lesions. Except for continuous progestin, medical therapies are limited. The levonorgestrel-releasing intrauterine device is an effective therapy for women who want to preserve fertility and avoid surgery. Surgical therapies include endometrial ablation methods that preserve the uterus; and hysterectomy, which results in high satisfaction rates but with potential surgical morbidity. Overall, hysterectomy and endometrial ablation result in the greatest satisfaction rates if future childbearing is not desired. Treatment of menorrhagia results in substantial improvement in quality of life.
Asunto(s)
Menorragia/cirugía , Adulto , Biopsia , Ablación por Catéter , Endometrio/patología , Femenino , Humanos , Histeroscopía , Terapia por Láser , Leiomioma/diagnóstico , Leiomioma/cirugía , Menorragia/diagnóstico , Menorragia/tratamiento farmacológico , Menorragia/fisiopatología , Menstruación/fisiología , Progestinas/administración & dosificación , Neoplasias Uterinas/diagnóstico , Neoplasias Uterinas/cirugíaAsunto(s)
Endometriosis/diagnóstico , Endometriosis/terapia , Dolor Pélvico/etiología , Dolor Pélvico/terapia , Administración Intravaginal , Antiinflamatorios no Esteroideos/uso terapéutico , Biomarcadores/análisis , Proteína C-Reactiva/análisis , Ablación por Catéter , Enfermedad Crónica , Ensayos Clínicos como Asunto , Anticonceptivos Femeninos/uso terapéutico , Danazol/administración & dosificación , Diagnóstico Diferencial , Quimioterapia Combinada , Endometriosis/complicaciones , Antagonistas de Estrógenos/administración & dosificación , Femenino , Hormona Liberadora de Gonadotropina/agonistas , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Infertilidad Femenina/etiología , Laparoscopía , Acetato de Medroxiprogesterona/uso terapéutico , Dolor Pélvico/diagnóstico , Guías de Práctica Clínica como Asunto , Reoperación , Índice de Severidad de la Enfermedad , Resultado del TratamientoAsunto(s)
Continuidad de la Atención al Paciente/normas , Endometriosis/diagnóstico , Endometriosis/tratamiento farmacológico , Comunicación Interdisciplinaria , Dolor Pélvico/tratamiento farmacológico , Dolor Pélvico/etiología , Acetaminofén/uso terapéutico , Adulto , Aminas/uso terapéutico , Analgésicos no Narcóticos/uso terapéutico , Analgésicos Opioides/uso terapéutico , Ansiolíticos/uso terapéutico , Enfermedad Crónica , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Diagnóstico Diferencial , Quimioterapia Combinada , Endometriosis/complicaciones , Femenino , Gabapentina , Humanos , Hidrocodona/uso terapéutico , Hipoglucemiantes/uso terapéutico , Dolor Pélvico/diagnóstico , Factores de Riesgo , Rosiglitazona , Trastornos Relacionados con Sustancias/complicaciones , Tiazolidinedionas/uso terapéutico , Trazodona/uso terapéutico , Neoplasias del Cuello Uterino/complicaciones , Ácido gamma-Aminobutírico/uso terapéutico , Displasia del Cuello del Útero/complicacionesRESUMEN
The American Society for Colposcopy and Cervical Pathology sponsored a consensus conference in 2001 to develop evidence-based guidelines for women with histologic abnormalities of the cervix. The options for management of cervical intraepithelial neoplasia 1, 2, and 3 are ranked according to the strength of the recommendation and the quality of the evidence. Follow-up with repeat cytology at six and 12 months or DNA testing for high-risk types of human papillomavirus at 12 months is the preferred management approach for women with cervical intraepithelial neoplasia 1 and satisfactory initial colposcopy. If results from repeat cytology are reported as atypical squamous cells of undetermined significance or greater, or if DNA human papillomavirus testing is positive for oncogenic types of the virus, repeat colposcopy is preferred. When the initial colposcopy is unsatisfactory, a diagnostic excisional procedure is preferred. Follow-up without treatment is acceptable only in women who are pregnant and adolescents with cervical intraepithelial neoplasia 1 who had unsatisfactory colposcopy. Biopsy-confirmed cervical intraepithelial neoplasia 2 and 3 requires treatment except during pregnancy and in compliant adolescents with cervical intraepithelial neoplasia 2 and negative endocervical curettage. When colposcopy is satisfactory, treatment includes ablative or excisional procedures. A diagnostic excisional procedure is recommended in women with biopsy-confirmed cervical intraepithelial neoplasia 2 or 3 and unsatisfactory colposcopy.
Asunto(s)
Cuello del Útero/patología , Displasia del Cuello del Útero/patología , Displasia del Cuello del Útero/terapia , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/terapia , Algoritmos , Biopsia , Colposcopía , Femenino , Humanos , Guías de Práctica Clínica como AsuntoRESUMEN
Group B streptococcus (GBS) is a leading cause of morbidity and mortality among newborns. Universal screening for GBS among women at 35 to 37 weeks of gestation is more effective than administration of intrapartum antibiotics based on risk factors. Lower vaginal and rectal cultures for GBS are collected at 35 to 37 weeks of gestation, and routine dindamycin and erythromycin susceptibility testing is performed in women allergic to penicillin. Women with GBS bacteriuria in the current pregnancy and those who previously delivered a GBS-septic newborn are not screened but automatically receive intrapartum antibiotics. Intrapartum chemoprophylaxis is selected based on maternal allergy history and susceptibility of GBS isolates. Intravenous penicillin G is the preferred antibiotic, with ampicillin as an alternative. Penicillin G should be administered at least four hours before delivery for maximum effectiveness. Cefazolin is recommended in women allergic to penicillin who are at low risk of anaphylaxis. Clindamycin and erythromycin are options for women at high risk for anaphylaxis, and vancomycin should be used in women allergic to penicillin and whose cultures indicate resistance to clindamycin and erytbromycin or when susceptibility is unknown. Asymptomatic neonates born to GBS-colonized mothers should be observed for at least 24 hours for signs of sepsis. Newborns who appear septic should have diagnostic work-up including blood culture followed by initiation of ampicillin and gentamicin. Studies indicate that intrapartum prophylaxis of GBS carriers and selective administration of antibiotics to newborns reduce neonatal GBS sepsis by as much as 80 to 95 percent.
Asunto(s)
Complicaciones Infecciosas del Embarazo/prevención & control , Infecciones Estreptocócicas/prevención & control , Streptococcus agalactiae , Profilaxis Antibiótica , Quimioprevención , Medios de Cultivo , Farmacorresistencia Bacteriana , Femenino , Humanos , Recién Nacido , Guías de Práctica Clínica como Asunto , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/epidemiología , Complicaciones Infecciosas del Embarazo/microbiología , Factores de Riesgo , Infecciones Estreptocócicas/diagnóstico , Infecciones Estreptocócicas/epidemiología , Vagina/microbiologíaRESUMEN
The American Society for Colposcopy and Cervical Pathology developed guidelines in 2001 for the management of cervical cytologic abnormalities. The guidelines incorporate the Bethesda System 2001 terminology and data from randomized studies of atypical squamous cells, low-grade intraepithelial lesions, human papillomavirus testing, and liquid-based cytology to formulate evidence-based recommendations. Each recommendation is graded according to the strength of the recommendation and the quality of the evidence, and specific terminology is added to highlight management options. The effectiveness of each triage recommendation is determined by the percentage of grade 2 and 3 cervical intraepithelial neoplasia it detects. Colposcopy, repeat cytology, and human papillomavirus DNA testing are acceptable options in women with atypical squamous cells of undetermined significance, but human papillomavirus DNA testing is preferred if liquid-based cytology is used. Colposcopy is recommended for women with a diagnosis of "atypical squamous cells-cannot rule out high-grade intraepithelial lesion." Women with low-grade squamous intraepithelial lesions should be referred for colposcopy, and women with high-grade lesions should undergo colposcopy and endocervical assessment. Colposcopy and endocervical sampling are recommended in women with all subcategories of atypical glandular cells. Endometrial sampling and colposcopy are recommended in women older than 35 years with atypical glandular cells and in younger women with unexplained vaginal bleeding. Women with a diagnosis of "atypical glandular cells-favor neoplasia" or adenocarcinoma-in-situ who are not found to have invasive disease on colposcopy should undergo a diagnostic excisional procedure, preferably a cold-knife conization.
Asunto(s)
Carcinoma de Células Escamosas/prevención & control , Displasia del Cuello del Útero/patología , Displasia del Cuello del Útero/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Frotis Vaginal , Biopsia , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/virología , ADN Viral/análisis , Femenino , Humanos , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/diagnóstico , Embarazo , Complicaciones Neoplásicas del Embarazo/patología , Complicaciones Neoplásicas del Embarazo/prevención & control , Complicaciones Neoplásicas del Embarazo/virología , Infecciones Tumorales por Virus/diagnóstico , Displasia del Cuello del Útero/terapia , Displasia del Cuello del Útero/virología , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/virologíaRESUMEN
The 2001 Bethesda System for reporting cervical or vaginal cytologic diagnoses is an incremental change in the uniform terminology introduced in 1988 and revised in 1991. The 2001 Bethesda System includes specific statements about specimen adequacy, general categorization, and interpretation and results. In the adequacy category, "satisfactory" and "unsatisfactory" are retained, but "satisfactory but limited by" is eliminated. The new category of "atypical squamous cells" (ASC) replaces the category of "atypical squamous cells of undetermined significance" (ASCUS) and is divided into qualifiers of (1) ASC of "undetermined significance" (ASC-US) and (2) "cannot exclude high-grade squamous intraepithelial lesion (HSIL)," or (ASC-H). The categories of ASCUS, "favor reactive" and "favor neoplasia" are eliminated. The terminology for low-grade squamous intraepithelial lesions (LSILs) and HSILs remains unchanged. The category of "atypical glandular cells of undetermined significance" (AGUS) is eliminated to avoid confusion with ASCUS and is replaced by the term "atypical glandular cells" (AGC), with attempts to identify whether the origin of the cells is endometrial, endocervical, or unqualified. "Endocervical adenocarcinoma in situ" and "AGC, favor neoplastic" are included as separate AGC categories. The presence of normal or abnormal endometrial cells is to be reported in women who are at least 40 years of age. Educational notes and comments on ancillary testing may be added as appropriate.